

DFW


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))				Docket No. 3153.00471	
In Re Application Of: Mohamad A. Morsey, et al.					
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/796,486	03/08/2004	[Stamp: OIPE, FEB 25 2005, PATENT & TRADEMARK SERVICE]	48924	1653	4033
Title: GROWTH HORMONE AND GROWTH HORMONE RELEASING HORMONE COMPOSITIONS					
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450					
37 CFR 1.97(b)					
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.					
37 CFR 1.97(c)					
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:					
<input type="checkbox"/> the statement specified in 37 CFR 1.97(e);					
OR					
<input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).					

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
3153.00471

In Re Application: Mohamad A. Morsey, et al.



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/796,486	03/08/2004		48924	1653	4033

Title: GROWTH HORMONE AND GROWTH HORMONE RELEASING HORMONE COMPOSITIONS

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 11-1449 as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**Certificate of Transmission by Facsimile***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)
_____ (Date)
_____ Signature
_____ Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on February 18, 2005 _____ (Date)
_____ Signature of Person Mailing Correspondence
MARIE M. LALLY Typed or Printed Name of Person Mailing Certificate


*This certificate may only be used if paying by deposit account.

Signature

Dated: February 18, 2005

KENNETH I. KOHN
KOHN & ASSOCIATES, PLLC
30500 NORTHWESTERN HWY.
SUITE 410
FARMINGTON HILLS, MICHIGAN 48334
(248) 539-5050

CC:



MANUAL OF PATENT EXAMINING PROCEDURE

PTO/SB/08 (2-92)

Sheet 1 of 1

Form PTO-1449				Docket Number (Optional) 3153.00471		Application Number 10/796,486	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Applicant Morsey, et al.			
				Filing Date 03/08/2004		Group Art Unit 1653	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
*	4980286	12/1990	Morgan, et al.				
*	5298422	03/1994	Schwartz, et al.				
*	5436146	07/1995	Shenk, et al.				
***	6423693	07/2002	Schwartz, et al.				
*	5756264	05/1998	Schwartz, et al.				
FOREIGN PATENT DOCUMENTS							
	DOCKET NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
***	WO 93/19698	10/1993	PCT				
***	WO 96/01092	01/1996	PCT				
***	715847	06/1996	EP				
***	1495735	12/1977	GB				
***	WO 88/04544	06/1988	PCT				
***	2154875	09/1985	GB				
***	WO 81/00356	02/1981	PCT				
***	WO 93/15788	08/1993	PCT				
***	WO 97/15342	05/1997	PCT				
***	WO 92/10576	06/1992	PCT				
***	WO 96/37514	11/1996	PCT				
***	0199018	10/1986	EP				
***	1052286	11/2000	EP				
*	WO 99/05300	02/1999	PCT				
*	WO 92/06180	04/1992	PCT				
*	WO 92/22635	12/1992	PCT				
*	WO 92/20316	11/1992	PCT				

*	WO 93/14188	07/1993	PCT				
*	WO 93/20221	10/1993	PCT				
*	WO 94/12649	06/1994	PCT				
*	WO 94/08598	04/1994	PCT				
OTHER DOCUMENTS (Including Author, Title, Date Pertinent Pages, Etc.)							
***		Felix, et al.; Pegylated Peptides IV Enhanced Biological Activity of site-directed pegylated GRF analogs; Int J. Peptide Protein Research; Vol. 46 pp. 253-264 (1995).					
***		Reecy, et al.; Structure and regulation of the porcine skeletal α -actin-encoding gene; GENE 180 pp. 23-28 (1996).					
***		Kubiak, et al.; Position 2 and Position 2/Ala ¹⁵ -Substituted Analogs of Bovine Growth Hormone-Releasing Factor (bGRF) with Enhanced Metabolic Stability and improved in Vivo Bioactivity; J. Med Chem. Vol. 36, pp. 888-897(1993).					
***		Breddam, et al.; Amidation of Growth Hormone releasing factor (1-29) by serine carboxypeptidase catalysed transpeptidation; Int J. Peptide Protein Res.; Vol. 37, pp. 153-160 (1991).					
***		Draghia-Akli, et al.; Enhanced growth by ectopic expression of growth hormone releasing hormone using an injectable myogenic vector Nature Biotechnology, Vol. 15, pp. 1285-1289 (1997).					
***		Hoffmann, et al.; Inhibition of dipeptidyl peptidase IV (DP IV) by anti-OP IV antibodies and non-substrate X-X-Pro- oligopeptides ascertained by capillary electrophoresis; J. of Chromatography A; Vol. 716 pp. 355-362(1995).					
**		Ling et al., Synthesis and in vitro bioactivity of human growth hormone-releasing factor analogs substituted at position-1, 1984, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol. 122, pp. 304-310.					
**		Frohman et al., Regulation growth hormone-releasing hormone gene expression and biosynthesis, 1989, THE YALE JOURNAL OF BIOLOGY AND MEDICINE, Vol. 62, pp. 427-433.					
**		Verma et al., Gene therapy-promises, problems and prospects, 1997, NATURE, Vol. 389, pp. 239-242					
**		Orkin et al, Report and recommendations of the panel to assess the NIH investment in research on gene therapy, 1995, www.nih.gov.					
**		Miller et al., Targeted vectors for gene therapy, 1995, FASEB J., pp. 190-199.					
*		Brar, et al.; Biosynthesis of Human Growth Hormone-Releasing Hormone (hGRH) in the Pituitary of hGRH Transgenic Mice; (1991) Endocrinology 129: 3274-3280.					
*		Arase, et al.; Effects on Feeding Behavior of Rats of a Cryptic Peptide from the C-Terminal End of Prepro-Growth Hormone-Releasing Factor (1987) Endocrinology 121:1960-1965.					
*		Vance; Growth-Hormone-Releasing Hormone; (1990) Clin. Chem. 36/3: 415-420.					
*		Frohman, et al.; Dipeptidylpeptidase IV and Trypsin-like Enzymatic Degradation of Human Growth Hormone releasing Hormone In Plasma; (1989) J. clin. Invest 83: 1533-1540.					
*		Etherton, et al.; Biology of Somatotropin in Growth and Lactation of Domestic Animals; (1998) Physiological reviews 78: 745-761.					
*		Etherton; Growth Hormone Technology Develops New Twist; Nature Biotechnology 15:1248.					
*		Benoist, et al.; In Vivo Sequence Requirements of the SV40 Early Promoter Region; (1981) Nature 290: 304-310.					
*		Yamamoto, et al.; Identification of a Functional Promoter in the Long Terminal Repeat of Rous Sarcoma Virus; (1980) Cell 22:787-797.					
*		Wagner, et al.; Nucleotide Sequence of the Thymidine Kinase Gene of Herpes Simplex Virus Type 1; Proc. Natl. Acad. Sci. USA 78: 1441-1445.					
*		Brinster, et al.; Regulation of Metallothionein-Thymidine Kinase Fusion Plasmids injected into Mouse Eggs; (1982) Nature 296:39-42.					
*		Villa-Kamaroff, et al.; A Bacterial Clone Synthesizing Proinsulin; (1978) Proc. Natl. Acad. Sci. USA 75: 3727-3731.					
*		DeBoer, et al.; The Tac Promoter A Functional Hybrid Derived from the trp and lac Promoters; (1983) Proc. Natl. Acad. Sci. USA 80: 21-25.					
*		Herrera-Estrella, et al.; Expression of Chimaeric Genes Transferred into Plant cell Using a Ti-plasmid-derived Vector Nature 303: 209-213.					
*		Herrera-Estrella, et al.; Light-Inducible and Chloroplast-Associated Expression of a Chimaeric Gene introduced into Nicotiana Tabacum Using a Ti Plasmid Vector; Nature 310: 115-120.					
*		Gardner, et al; Abstract; (1981) Nucleic Acid Research; 9:2871-2888.					
*		Swift, et al; Tissue-Specific Expression of the Rat Pancreatic Elastase I Gene in Transgenic Mice; (1984) Cell 38: 639-646.					
*		Ornitz, et al.; Elastase I Promoter Directs Expression of Human Growth Hormone and SV40 T Antigen Genes to Pancreatic Acinar Cells in Transgenic Mice; (1986) Cold Spring Harbor Symp. Quant. Bio. 50: 399-409.					
*		McDonald, et al.; Diminished Responsiveness of Male Homosexual chronic Hepatitis B Virus Carriers					

		with HTLV-III Antibodies to Recombinant α -Interferon; (1987) <i>Hepatology</i> 7:719-723.
*		Grosschedl, et al.; Introduction of a μ Immunoglobulin Gene into the Mouse Germ Line: Specific Expression in Lymphoid cells and synthesis of Functional Antibody; (1984) 38: 647-658.
*		J. M. Adams, et al.; The c-myc Oncogene Driven by Immunoglobulin Enhancers Induces Lymphoid Malignancy in Transgenic Mice; (1985) <i>Nature</i> 318: 533-538.
*		Alexander, et al.; Expression of the c-myc Oncogene Under Control of an Immunoglobulin Enhancer in E μ -myc Transgenic Mice; (1987) <i>Mol. Cellular Biology</i> ; 7:1436-1444.
*		Leder, et al.; Consequences of Widespread Deregulation of the c-myc Gene in Transgenic Mice: Multiple Neoplasms and Normal Development; (1986) <i>Cell</i> 45: 485-495.
*		Pinkert, et al.; An Albumin Enhancer Located 10 kb Upstream Functions along with its Promoter to Direct Efficient, Liver-Specific Expression in Transgenic Mice; (1987) <i>Genes and Devel.</i> 1:268-276.
*		Krumlauf, et al.; Developmental Regulation of α -Fetoprotein Genes In Transgenic Mice; (1985) <i>Mol. Cell. Bio.</i> 5:1639-1648.
*		Hammer, et al.; Diversity of Alpha-Fetoprotein Gene Expression in Mice Is Generated by a Combination of Separate Enhancer Elements; (1987) <i>Science</i> 235: 53-58.
*		Kelsey, et al.; Species and Tissue-Specific Expression of Human α_1 -Antitrypsin in Transgenic Mice; (1987) <i>Genes Devel.</i> 1: 161-171.
*		Magram, et al.; Developmental Regulation of a Cloned Adult β -Globin Gene in Transgenic Mice; (1985) <i>Nature</i> 315: 338-340.
*		Readhead, et al; Expression of a Myelin Basic Protein Gene in Transgenic Shiverer Mice; Correction of the Dysmyelinating Phenotype; (1987) <i>Cell</i> 48: 703-712.
*		Shani; Tissue-Specific Expression of Rat Myosin Light-Chain 2 Gene in Transgenic Mice; (1985) <i>Nature</i> 314: 283-286.
*		Reecy, et al.; Multiple Regions of the Porcine α -Skeletal Actin Gene Modulate Muscle-Specific Expression in Cell culture and Directly injected Skeletal Muscle; (1998) <i>Animal Biotechnology</i> 9:101-120.
*		Mason, et al.; The Hypogonadal Mouse: Reproductive Functions Restored by Gene Therapy; (1995) <i>Science</i> 234: 1372-1378.
*		Wigler, et al.; Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells; (1977) <i>Cell</i> 11:223-232.
*		Szybalska & Szybalski; Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of Biochemical Trait; (1962) <i>Proc. Natl. Acad. Sci. USA</i> 48: 2026.
*		Lowy, et al.; isolation of Transforming DNA: Cloning the Hamster Aprt Gene; (1980) <i>Cell</i> 22: 817-823.
*		Wigler, et al.; Transformation of Mammalian with an Amplifiable Dominant-Acting Gene; (1980) <i>Natl. Acad. Sci.</i> 77:3567-3570.
*		O'Hare, et al.; Transformation of Mouse Fibroblasts to Methotrexate Resistance by a Recombinant Plasmid Expressing a Prokaryotic Dehydrofolate Reductase; (1981) <i>Proc. Natl. Acad. Sci. USA</i> 78: 1527-1531.
*		Mulligan, et al.; Selection for Animal Cells that Express the Escherichia Coli Gene Coding for Xanthine-Guanine Phosphoribosyltransferase; (1981) <i>Proc. Natl. Acad. Sci. USA</i> 78: 2072-2076.
*		Colbere-Garapin, et al.; A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells; (1981) <i>J. Mol. Biol.</i> 150:1-14.
*		Santerre, et al; Expression of Prokaryotic Genes for Hygromycin B and G418 Resistance as Dominant-Selection Markers in Mouse L Cells; (1984) <i>Gene</i> 30: 147-156.
*		Goldspiel, et al.; Human Gene Therapy; (1993) <i>Clinical Pharmacy</i> 12: 488-505.
*		Wu, et al.; Delivery Systems for Gene Therapy (1991) <i>Biotherapy</i> 3: 87-95.
*		Tolstoshev; Gene Therapy, Concepts, current Trials and Future Directions; (1993) <i>Ann. Rev. Pharmacol. Toxicol.</i> 32: 573-596.
*		Mulligan; The Basic Science of Gene Therapy; (1993) <i>Science</i> 260: 926-932.
*		Morgan, et al.; Human Gene Therapy; (1993) <i>Annual Rev. Biochem.</i> 62:191-217.
*		Editorial; Gene Therapy — Proceeding from Laboratory to Clinic; (1993) <i>Tibtech</i> 11(5) 155-215.
*		Koller, et al.; inactivating the β_2 -microglobulin Locus in Mouse Embryonic Stem Cells by Homologous Recombination; (1989) <i>Proc. Natl. Acad. Sci. USA</i> 86: 8932-8935.
*		Zijlstra, et al.; Germ-line Transmission of a disrupted microglobulin Gene Produced by Homologous Recombination In Embryonic Stem Cells; (1989) <i>Nature</i> 342: 435-438.
*		Wu, et al.; Receptor-Mediated in Vitro Gene Transformation by a Soluble DNA Carrier System; (1987) <i>J. Biological Chem.</i> 262:4429-4432.
*		Miller, et al.; Use of Retroviral Vectors for Gene Transfer and Expression; (1993) <i>Methods in Enzymology</i> 217: 581-599.
*		Boesen, et al.; Circumvention of Chemotherapy-induced Myelosuppression by Transfer of the mdrl Gene; (1994) <i>Biotherapy</i> 6: 291-302.
*		Clowes, et al.; Long-Term Biological Response of injured Rat Carotid Artery Seeded with Smooth Muscle Cells Expressing Retrovirally Introduced Human Genes; (1994) <i>J. Clin. invest</i> 93: 644-651.
*		Kiem, et al.; Retrovirus-Mediated Gene Transduction Into Canine Peripheral Blood repopulating Cells; (1994) <i>Blood</i> 83: 1467-1473.
*		Grossman, et al.; Retroviruses: Delivery Vehicle to the Liver (1993) <i>Current Opin. In Genetics and Devel.</i>

	3: 110-114.		
*	Bout, et al.; Lung Gene Therapy: in Vivo Adenovirus-Mediated Gene Transfer to Rhesus Monkey Airway Epithelium; (1994) Human Gene Therapy 5:3-10.		
*	Rosenfeld, et al.; Adenovirus-Mediated Transfer of a Recombinant al-Antitrypsin Gene to the Lung Epithelium in Vivo; (1991) Science 252: 431-434.		
*	Rosenfeld, et al.; In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium; (1992) Cell 68:143-155.		
*	Mastrangeli, et al.; Diversity of Airway Epithelial Cell Targets for in Vivo Recombinant Adenovirus-Mediated Gene Transfer (1993) J. Clin. investigation 91: 225-234.		
*	Wang, et al.; A Packaging Cell Line for Propagation of Recombinant Adenovirus Vectors Containing two Lethal Gene-Region Deletions; (1995) Gene Therapy 2: 775-783.		
*	Walsh, et al.; Gene Therapy for Human Hemoglobinopathies; (1993) Proc. Soc. Exp. Biol. Med. 204: 289-300.		
*	Loeffler, et al.; Gene Transfer into Primary and Established Mammalian Cell Lines with Lipopolyamine-Coated DNA; (1993) Methods in Enzymology 217: 599-618.		
*	Cotton, et al.; Receptor-Mediated Transport of DNA into Eukaryotic Cells; (1993) Methods in Enzymol. 217: 618-644.		
*	Cline; Perspectives for Gene Therapy: Inserting New Genetic Information into Mammalian Cells by Physical Techniques and Viral Vectors; (1985) Pharmac. Ther. 29: 69-92.		
*	Stemple, et al.; isolation of Stem Cell for Neurons and Glia From the Mammalian Neural Crest; (1992) Cell 71: 973-985.		
*	Rheinwald; Serial Cultivation of Normal Human Epidermal Keratinocytes; (1960) Methods in Cell Biology 21A: 229-254.		
*	Pitteikow, et al.; New Techniques for the In Vitro Culture of Human Skin Keratinocytes and Perspectives on Their Use for Grafting of Patients with Extensive Burns; (1986) Mayo Clinic Proc. 61: 771-777.		
*	Langer New Methods of Drug Delivery; Science (1990)249: 1527-1533.		
*	Treat, et al.; Liposome Encapsulated Doxorubicin Preliminary Results of Phase I and II Trials; Liposomes in the Therapy of infectious Disease and Cancer (1989) 353-365.		
*	Lopez-Berestein; Treatment of Systemic Fungal Infections with Liposomal-amphotericin B; Liposomes in the Therapy of Infectious Disease and Cancer 31 7-327.		
*	Sefton; Implantable Pumps; CRC Critical Reviews in Biomed. Engineering 14: 201-240.		
*	Buchwald, et al.; Long-Term Continuous Intravenous Heparin Administration by an implantable Infusion Pump in Ambulatory Patients with Recurrent Venous Thrombosis; (1980) Surgery 88: 507-516.		
*	Saudek, et al.; A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery; (1989) The New England J. of Medicine 321: 574-579.		
*	Langer, et al.; Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review; (1983) J. Macromol. Chem. Phys. 23: 61-126.		
*	Abstract; Science 228: (1985) 190-192.		
*	During, et al.; Controlled Release of Dopamine From a Polymeric Brain Implant In Vivo Characterization; (1989) Ann. Neurol. 25: 351-356.		
*	Howard, et al.; Intracerebral Drug Delivery in Rats with Lesion-Induced Memory Deficits; (1989) J. Neurosurg. 71: 105-112.		
*	Goodson; (1984) Dental Applications; Medical Applications of Controlled Release, Vol. II 115-138.		
*	Joliet, Proc. Natl. Acad. Sci. USA (1991) 1864-1868.		
*	Kollas, et al.; Regulated Expression of Human γ -, β -, and Hybrid $\gamma\beta$ -Globin Genes in Transgenic Mice; Manipulation of the Developmental Expression Patterns; (1986) Cell 46: 89-94.		
<table border="1" style="width: 100%;"> <tr> <td style="width: 50%; text-align: center;">EXAMINER</td> <td style="width: 50%; text-align: center;">DATE CONSIDERED</td> </tr> </table>		EXAMINER	DATE CONSIDERED
EXAMINER	DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

* copies of references provided in parent application USSN 09/546,411

**copies of references cited by Examiner in parent application USSN 09/546,411

***copies of references provided in parent application USSN 09/628,730